Key result
T cell-targeting nanotherapies emerge as a promising precision approach to modulate atherosclerosis inflammation.
Answers are grounded in this paper and cite their sources.
T cell-targeting nanotherapies represent a promising strategy to modulate the inflammatory imbalance underlying atherosclerosis.
Cardiovascular diseases remain the leading cause of mortality worldwide. Specifically, atherosclerosis is a primary cause of acute cardiac events. However, current therapies mainly focus on lipid-lowering versus addressing the underlying inflammatory response that leads to its development and progression. Nanoparticle-mediated drug delivery offers a promising approach for targeting and regulating these inflammatory responses. In atherosclerotic lesions, inflammatory cascades result in increased T helper (Th) 1 and Th17 activity and reduced T regulatory activation. The regulation of T cell responses is critical in preventing the inflammatory imbalance in atherosclerosis, making them a key therapeutic target for nanotherapy to achieve precise atherosclerosis treatment. By functionalizing nanoparticles with targeting modalities, therapeutic agents can be delivered specifically to immune cells in atherosclerotic lesions. In this Review, we outline the role of T cells in atherosclerosis, examine current nanotherapeutic strategies for targeting T cells and modulating their differentiation, and provide perspectives for the development of nanoparticles specifically tailored to target T cells for the treatment of atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Lambaren et al. (2025) conducted a review in Atherosclerosis. T Cell-Targeting Nanotherapies was evaluated. T cell-targeting nanotherapies offer a promising approach for precise atherosclerosis treatment by modulating inflammatory responses and T cell differentiation.
Synapse has enriched 10 related papers. Consider them for comparative context: